EU Regulators Tackle "Significant Benefit" Criteria For Orphan Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
EC is working on update to its 2003 orphan drug communication, noting requirement that orphan drugs provide significant benefit over existing treatments has become "increasingly complex."